|
Stryker Settles for $15 Million in Bone Filler Misbranding Case
Stryker’s Biotech division has agreed to pay $15 million to the U.S. government to settle an illegal scheme to promote off-label use of its OP-1 implant and OP-1 putty in combination with Calstrux, a bone-void filler.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives